<DOC>
	<DOCNO>NCT02905565</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , add-on standard-of-care study primary objective ass safety NBP treatment patient mild moderate acute ischemic stroke . The secondary objective include determination PK profile exploratory evaluation efficacy NBP treatment stroke patient .</brief_summary>
	<brief_title>n-Butylphthalide ( NBP ) Softgel Capsules Stroke Patients</brief_title>
	<detailed_description />
	<mesh_term>3-n-butylphthalide</mesh_term>
	<criteria>Inclusion Criteria Subjects eligible include study follow criterion apply : 1 . Males female age ≥ 18 ≤ 80 year 2 . Women childbearing potential ( WOCBP ) must negative urine HCG pregnancy test Screening practice medically acceptable method contraception annual failure rate le 1 % completion trial 60 day discontinuation study treatment . Women consider childbearing &gt; 1 year postmenopausal surgically sterile ( ie , hysterectomy , bilateral oophorectomy , bilateral salpingectomy tubal ligation ) . Examples approve contraception oral progestogen , oral combine contraceptive estrogen progesterone , Depo injection , transdermally deliver contraceptive , IUD , vaginal ring , diaphragm spermicide condom , condom spermicide ; bilateral tubal ligation . Vasectomy male partner along second method approve contraception abstinence long subject agree engage sexual activity throughout duration trial 3 . A clinical diagnosis mild moderate cortical subcortical AIS 4 . Able swallow softgel capsule assess swallow evaluation 5 . Completes screen procedure study treatment first administer within 12 hour stroke onset . The stroke onset time define last time individual experience current acute stroke symptom 6 . A standard NIHSS score 6 20 and/or ageadjusted NIHSS score 19 30 , inclusive ( calculated [ age years/5 ] + standard NIHSS score ) 7 . Fully conscious screen process ( slight drowsiness acceptable ) correspond Level Consciousness score NIHSS assessment 0 1 8 . Functionally independent , define Modified Rankin Scale ( mRS ) score 0 1 present illness determine subject provide representative subject unable participate time study entry ( determined retrospective assessment Investigator ) 9 . Capable understanding sign , write , ICF ; subject capable time enrollment , authorized representative must provide write informed consent subject provide capable 10 . Agrees comply protocol requirement Exclusion Criteria Subjects exclude study follow criterion apply : 1 . Female subject pregnant , lactating/breastfeeding , plan become pregnant within next 3 month 2 . Suspected diagnosis cortical subcortical AIS , opinion Investigator , may cause present symptom 3 . Rapidly improve resolve symptom , suggest possible transient ischemic attack ( TIA ) rather qualify stroke 4 . Signs hemorrhage cause acute stroke symptom ( early ischemic finding ) cranial image Screening 5 . History intracranial hemorrhage 6 . Seizure onset stroke 7 . Treated ( expect treat ) hospitalization medication cerebral edema due stroke ( eg , glycerol mannitol ) 8 . A previous clinical diagnosis stroke exclude subject ( however , individual previously undiagnosed stroke evidence screen CT MRI may enrol provide affect neurological functional assessment base opinion Investigator ) 9 . Treated plan treat tPA ( acute thrombolytic ) endovascular therapy ; however , anticoagulant use approved dos permissible 10 . Uncontrolled severe hypertension define systolic BP ( SBP ) ≥ 220 mm Hg diastolic BP ( DBP ) ≥ 110 mm Hg 11 . Treatment intensive antihypertensive therapy , intravenous ( IV ) sodium nitroprusside ( Nipride® ) and/or 30 mg IV labetalol , onset AIS randomization study treatment 12 . SBP &lt; 100 mm Hg , temperature &gt; 38.0º C , heart rate &lt; 40 beats/minute &gt; 120 beats/minute Screening prior randomization 13 . A glucose level &lt; 50 mg/dL Screening 14 . An international normalized ratio ( INR ) ≥ 1.5 treated anticoagulant therapy , INR ≥ 3.5 treat acceptable anticoagulant therapy 15 . A serum ALT AST level &gt; 1.5 × ULN , bilirubin &gt; 1.5 ULN ( except set know Gilbert 's disease ) Screening 16 . Clinically significant renal dysfunction ( include serum creatinine level &gt; 2.0 mg/dL 177 μmol/L ) Screening 17 . A hemoglobin level &lt; 11 g/dL Screening 18 . Current within last 6 month prior Screening , New York Heart Association Class III/IV heart failure , severe uncorrected valve disease , know suspect infective/vegetative endocarditis , ventricular tachycardia , torsade de point ; 19 . Corrected QT &gt; 450 ms male subject &gt; 470 ms female subject Screening Baseline ( average 3 tracing ) ECGs 20 . Current diagnosis cancer treat received treatment cancer within last 5 year ( except basal cell carcinoma ) 21 . Known life expectancy &lt; 6 month ( reason ) 22 . Known allergy hypersensitivity celery soybeans 23 . Received treatment investigational drug within 30 day Day 1 , previously treat NBP , currently participate another clinical study 24 . History alcohol drug dependence , know abused alcohol ( eg , intoxicate ) within last 24 hour confirm drug abuse Screening 25 . History hepatitis B , hepatitis C , HIV , TB</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Multicenter</keyword>
	<keyword>Randomized</keyword>
	<keyword>Double-Blind</keyword>
	<keyword>Placebo-Controlled</keyword>
	<keyword>Add-On Standard-of-Care</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
</DOC>